Cancer Immunology, Immunotherapy

, Volume 63, Issue 9, pp 969–975

Engineered T cells for cancer therapy

  • Carl H. June
  • Marcela V. Maus
  • Gabriela Plesa
  • Laura A. Johnson
  • Yangbing Zhao
  • Bruce L. Levine
  • Stephan A. Grupp
  • David L. Porter
Focussed Research Review

DOI: 10.1007/s00262-014-1568-1

Cite this article as:
June, C.H., Maus, M.V., Plesa, G. et al. Cancer Immunol Immunother (2014) 63: 969. doi:10.1007/s00262-014-1568-1

Abstract

It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this focused research review.

Keywords

Adoptive cell transfer Gene transfer Leukemia Chimeric antigen receptor 19th Danish Cancer Society Symposium 

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Carl H. June
    • 1
    • 4
  • Marcela V. Maus
    • 1
    • 2
  • Gabriela Plesa
    • 1
  • Laura A. Johnson
    • 1
    • 4
  • Yangbing Zhao
    • 1
    • 4
  • Bruce L. Levine
    • 1
    • 4
  • Stephan A. Grupp
    • 1
    • 3
  • David L. Porter
    • 1
    • 2
  1. 1.Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Division of OncologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  4. 4.Department of Pathology and Laboratory Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations